Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data

Movement Disorders : Official Journal of the Movement Disorder Society
Keith L DavisJeffery K Allen

Abstract

We estimated the prevalence of medication nonadherence in Parkinson's disease (PD) and the association between treatment nonadherence and healthcare costs. Insurance claims from over 30 US health plans were analyzed. Inclusion criteria were as follows: PD diagnosis, >or=1 PD-related prescription between 1/1/1997 and 12/31/2004, continuous health plan enrollment for >or=6 months before and >or=12 months after first PD prescription. Adherence, all-cause healthcare utilization, and all-cause costs were evaluated over 12 months post-treatment initiation. Adherence was measured using the medication possession ratio (MPR), with MPR < 0.8 defining nonadherence. Among patients identified for inclusion (N = 3,119), 58% were male and mean age was 69 years. Mean MPR was 0.58 and 61% of patients were nonadherent. Unadjusted mean medical costs were significantly higher (P < 0.01) among nonadherers ($15,826) compared with adherers ($9,228), although nonadherers had lower prescription drug costs ($2,684 vs. $3,854; P < 0.05). After controlling for confounders in multivariable analyses, a large positive relationship between nonadherence and both medical and total healthcare costs remained (+$3,451, P < 0.0001 and +$2,383, P = 0.0053, respectiv...Continue Reading

References

Mar 1, 1987·Controlled Clinical Trials·R B Haynes, R Dantes
Feb 1, 1984·Annals of Internal Medicine·S A ErakerM H Becker
Jan 1, 1997·Journal of Clinical Epidemiology·J F Steiner, A V Prochazka
Apr 1, 1997·Seizure : the Journal of the British Epilepsy Association·D BuckD W Chadwick
Feb 6, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·O RascolF Stocchi
Dec 26, 2001·Journal of Clinical Epidemiology·J Dunbar-Jacob, M K Mortimer-Stephens
Jan 5, 2002·PharmacoEconomics·D A HughesT Walley
May 10, 2002·Pharmacoepidemiology and Drug Safety·Olivia LeoniGianmario Frigo
Dec 11, 2002·JAMA : the Journal of the American Medical Association·R Brian HaynesAmit X Garg
Sep 27, 2003·Clinical Therapeutics·Anke RichterSusan L Dennett
May 11, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Norman A LeopoldMarcia R Hurka
Jul 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel M HuseGregory Lenhart
Jul 23, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine A GrossetDonald G Grosset
Aug 5, 2005·Canadian Journal on Aging = La Revue Canadienne Du Vieillissement·Colleen MetgeMarina Yogendran
Aug 11, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine A GrossetDonald G Grosset
Oct 8, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Katia NoyesAndrew W Dick
Mar 4, 2006·Pharmacoepidemiology and Drug Safety·Susan E AndradeK Arnold Chan
Mar 16, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Jordan J ElmUNKNOWN NINDS NET-PD Investigators and Coordinators
Dec 13, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Amit S KulkarniMark A Stacy

❮ Previous
Next ❯

Citations

May 3, 2011·Journal of General Internal Medicine·Jerry L GrenardWalid F Gellad
Aug 21, 2013·Current Neurology and Neuroscience Reports·Jori E Fleisher, Matthew B Stern
Aug 1, 2012·Journal of the International Neuropsychological Society : JINS·Eva PirogovskyPaul E Gilbert
Dec 14, 2011·The Clinical Neuropsychologist·Kevin J ManningPaul J Moberg
Sep 21, 2013·Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association·Tapani Keränen, Sammeli Liikkanen
Apr 28, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V SchapiraUNKNOWN Pramipexole ER Studies Group
Jun 28, 2011·BMC Health Services Research·François-Emery Cotté, Gérard De Pouvourville
Apr 14, 2012·Clinical Interventions in Aging·Eva-Maria HametnerWerner Poewe
Oct 30, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Carmen Rodríguez-BlázquezPablo Martínez-Martín
Sep 7, 2013·Current Medical Research and Opinion·Jan-Peer ElshoffLars Bauer
Oct 1, 2015·Journal of Clinical Nursing·Ju Young Shin, Barbara Habermann
Dec 17, 2014·CNS Drugs·Naveed Malek, Donald G Grosset
Jul 28, 2016·Multiple Sclerosis and Related Disorders·Charity EvansHelen Tremlett
Jun 9, 2016·Neurology and Therapy·Aline Aparecida FoppaMareni Rocha Farias
May 26, 2016·The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses·Ju Young Shin, Barbara Habermann
Oct 1, 2016·Assistive Technology : the Official Journal of RESNA·Jaclyn K Schwartz
Apr 24, 2012·Journal of the Neurological Sciences·Diego Santos-GarcíaRaúl de la Fuente-Fernández
Mar 19, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Yu-Jung WeiClayton H Brown
Jan 1, 2011·Journal of Central Nervous System Disease·Paul S Fishman
Jun 1, 2019·Expert Opinion on Pharmacotherapy·Alexander S Wang, Steven A Gunzler
Jul 10, 2019·Journal of Parkinson's Disease·Werner PoeweAngelo Antonini
Oct 28, 2015·Movement Disorders Clinical Practice·Lisette Bazán-RodríguezMayela Rodríguez-Violante
Aug 31, 2017·Annals of Biomedical Engineering·Amanda Gomes RabeloAdriano O Andrade
Apr 12, 2016·Journal of Parkinson's Disease·Jori E FleisherJudy A Shea
Apr 8, 2011·Acta Neurologica Scandinavica·J LökkG Ljunggren
Aug 11, 2020·Movement Disorders Clinical Practice·Michelle H S TosinBeatriz Guitton R B Oliveira
Dec 20, 2017·Journal of Parkinson's Disease·Bastiaan R BloemNienke M De Vries
Oct 9, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Nabila DahodwalaJalpa A Doshi
Sep 20, 2020·Neurobiology of Aging·Joyce SimRobert Hester
Apr 13, 2021·Journal of Parkinson's Disease·Diego Santos GarcíaUNKNOWN COPPADIS Study Group
Apr 29, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Alfonso FasanoLydia Vela-Desojo
May 11, 2021·Neurodegenerative Disease Management·Adrian I EspirituRoland Dominic G Jamora
Jul 9, 2021·Patient Preference and Adherence·Gabriele Helga FrankeTino Prell
Jul 29, 2021·International Journal of Clinical Pharmacy·Sabrina Anne JacobSara Lai Heong Lew
Oct 22, 2016·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Jaclyn K Schwartz, Roger O Smith
Nov 15, 2017·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Jaclyn K SchwartzRoger O Smith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The American Journal of Geriatric Pharmacotherapy
Marcy L TarrantsDongmu Zhang
Journal of the Neurological Sciences
D Grosset, European PD Therapy Compliance Study Group
Movement Disorders : Official Journal of the Movement Disorder Society
K A GrossetD Grosset
Movement Disorders : Official Journal of the Movement Disorder Society
D GrossetK A Grosset
© 2021 Meta ULC. All rights reserved